Core Insights - The combination of insulin pumps and Continuous Glucose Monitoring (CGM) is becoming central to the global diabetes device competition [2] - MiniMed's 780G automated insulin delivery system has received CE certification and can now work with Abbott's Instinct CGM sensor, indicating a shift towards a multi-sensor ecosystem [3][5] Group 1: MiniMed 780G System - The MiniMed 780G is one of the more mature automated insulin delivery systems on the market, capable of automatically adjusting insulin delivery through algorithms [4] - The system can manage insulin delivery even when patients forget to input meal information or inaccurately estimate carbohydrates [4][6] - The integration with Abbott's Instinct CGM sensor is seen as a significant move to strengthen MiniMed's product ecosystem post-separation from Medtronic [13] Group 2: Industry Trends - The insulin pump ecosystem is transitioning from a "closed system" to a "platform-based" approach, allowing for interoperability between devices from different manufacturers [15][17] - The rapid development of CGM technology is outpacing that of insulin pumps, prompting manufacturers to support multiple sensors [18][20] - Patients are becoming more sensitive to device choices, leading to a demand for open AID ecosystems [21][22] Group 3: Opportunities and Challenges in China - The diabetes device market in China is one of the fastest-growing sectors in medical devices [23] - Domestic companies are focusing on CGM and insulin pump manufacturing, with some exploring AID systems [24] - Chinese firms face challenges in algorithm capabilities and device ecosystems compared to global leaders [25][29] - Future competition may center around comprehensive diabetes management platforms rather than individual products [30]